What's Next for Nasdaq After Meta and Microsoft Soared
On Thursday, Meta Platforms (META) and Microsoft (MSFT) sent Nasdaq (QQQ) to all-time highs intraday to cap a strong July 2025 stock market.Meta stock traded as high as $784.75 before closing at $773.44, up by 11.25%. It earned $7.14 a share, beating estimates by nearly $1.25. Revenue jumped to $47.52 billion, up by 21.6% Y/Y. Investors who avoided the magnificent seven on concerns of valuations in the last two years missed out.Meta’s guidance is impressive. It is forecasting up to $50.5 billion in revenue, compared to the $45 billion consensus. In 2025, Meta will spend $114 billion to $118 billion. It continues to invest in artificial intelligence initiatives.Microsoft (MSFT) traded as high as $555.45 yesterday, then closed at $533.50 (+3.95%). Azure growth accelerated, rebounding from prior slowdowns. Driven by the AI contribution, Azure will continue to lift its Intelligent Cloud revenue.The two firms failed to keep Nasdaq from closing at a record high. Ongoing macroeconomic headwinds from tariffs hurt shares of Tesla (TSLA), Alphabet (GOOG), Broadcom (AVGO), Qualcomm (QCOM), and Micron (MU). Stretched valuations may shrink if the market’s bullish sentiment reverses.Investors should continue to wait for META and MSFT stock to pull back before adding to the long-term position. They have a commanding lead in their core business of advertising and cloud AI, respectively. Their investments in AI will keep them ahead of the competition.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


